Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting

Results contribute to growing body of evidence in support of elismetrep, a TRPM8 migraine-associated channel blocker (MACB), to help address the debilitating impact of migraine

Novel liquid-filled softgel capsule (LSGC) formulation results in earlier and more rapid absorption compared to the formulation used in Phase 2b

Preclinical studies demonstrate additive efficacy with other migraine therapeutics including gepants and triptans

Phase 3 studies anticipated to initiate in mid-2026